Closed-loop in Adults With T2D Not Requiring Dialysis (AP-Renal)
Type 2 Diabetes

About this trial
This is an interventional treatment trial for Type 2 Diabetes focused on measuring diabetes, type 2 diabetes, closed-loop, artificial pancreas, insulin pump therapy, continuous glucose monitoring
Eligibility Criteria
Inclusion Criteria:
- Age 18 years or over
- Diagnosis of type 2 diabetes using standard diagnostic practice
- Current treatment with subcutaneous insulin
- Screening HbA1c ≤ 11% (97mmol/mol) on analysis from local laboratory
- Subject is willing to perform regular finger-prick blood glucose monitoring
- Willingness to wear study devices
- Literate in English
Exclusion Criteria:
- Physical or psychological condition likely to interfere with the normal conduct of the study and interpretation of the study results as judged by the investigator
- Known or suspected allergy to insulin
- Lack of reliable telephone facility for contact
- Pregnancy, planned pregnancy, or breast feeding
- Severe visual impairment
- Severe hearing impairment
- Medically documented allergy towards the adhesive (glue) of plasters
- Serious skin diseases located at places of the body, which potentially are possible to be used for localisation of the glucose sensor
- Illicit drugs abuse
- Prescription drugs abuse
- Alcohol abuse
Sites / Locations
- Cambridge University Hospitals NHS Foundation Trust
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Closed loop insulin delivery
Standard therapy
Unsupervised home use of day and night fully automated closed loop insulin delivery system (CamAPS HX) for 8 weeks The CamAPS HX closed-loop system comprises: Dana insulin pump (Diabecare, Sooil, Seoul, South Korea) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA) An Android smartphone hosting CamAPS HX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump Glooko/Diasend cloud upload system to monitor CGM/insulin data
Participants in the control arm will continue to follow their current diabetes management plan for the 8 week study period. Participants will be wear a masked continuous glucose monitoring (CGM) system during the 8 week study period